DE60320933D1 - Rho-kinase inhibitoren - Google Patents

Rho-kinase inhibitoren

Info

Publication number
DE60320933D1
DE60320933D1 DE60320933T DE60320933T DE60320933D1 DE 60320933 D1 DE60320933 D1 DE 60320933D1 DE 60320933 T DE60320933 T DE 60320933T DE 60320933 T DE60320933 T DE 60320933T DE 60320933 D1 DE60320933 D1 DE 60320933D1
Authority
DE
Germany
Prior art keywords
rho
kinase inhibitors
kinase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320933T
Other languages
English (en)
Inventor
Dhanapalan Nagarathnam
Uday Khire
Davoud Asgari
Jianxing Shao
Xiao-Gao Liu
Chunguang Wang
Barry Hart
Olaf Weber
Mark Lynch
Lei Zhang
Lei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of DE60320933D1 publication Critical patent/DE60320933D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
DE60320933T 2002-01-10 2003-01-10 Rho-kinase inhibitoren Expired - Lifetime DE60320933D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34662802P 2002-01-10 2002-01-10
PCT/US2003/000606 WO2003059913A1 (en) 2002-01-10 2003-01-10 Roh-kinase inhibitors

Publications (1)

Publication Number Publication Date
DE60320933D1 true DE60320933D1 (de) 2008-06-26

Family

ID=23360296

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60320933T Expired - Lifetime DE60320933D1 (de) 2002-01-10 2003-01-10 Rho-kinase inhibitoren

Country Status (8)

Country Link
US (3) US20040014755A1 (de)
EP (1) EP1465900B1 (de)
JP (1) JP4505228B2 (de)
AU (1) AU2003202263A1 (de)
CA (1) CA2472619A1 (de)
DE (1) DE60320933D1 (de)
ES (1) ES2305435T3 (de)
WO (1) WO2003059913A1 (de)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008658A (es) * 2001-03-23 2005-04-11 Bayer Ag Inhibidores de rho-cinasa.
DE60218138T2 (de) * 2001-03-23 2007-09-20 Bayer Pharmaceuticals Corp., West Haven Rho-kinase inhibitoren
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
CA2583259C (en) * 2004-10-08 2011-08-02 Astellas Pharma Inc. Aromatic ring fused pyrimidine derivative
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
DK1869037T3 (da) 2005-03-25 2011-10-24 Tibotec Pharm Ltd Heterobicykliske inhibitorer af HVC
DE102005019201A1 (de) * 2006-04-19 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
AR054122A1 (es) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas
JP4972551B2 (ja) 2005-06-21 2012-07-11 興和株式会社 緑内障の予防又は治療剤
US20070135499A1 (en) * 2005-07-11 2007-06-14 Aerie Pharmaceuticals, Inc. Hydrazide compounds
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP1905452B1 (de) 2005-07-12 2013-06-19 Kowa Company, Ltd. Wirkstoff zur prävention oder behandlung von glaukomen
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
MX2008008328A (es) 2005-12-22 2008-09-15 Alcon Res Ltd (indazol-5-il)-pirazinas y (1,3-dihidro-indol-2-ona)-pirazinas para tratar enfermedades y condiciones mediadas con rho cinasa.
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US20090247554A1 (en) * 2006-03-30 2009-10-01 Takeda San Diego, Inc. Kinase inhibitors
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
EP2068878B1 (de) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho-kinase-hemmer
BRPI0718592A2 (pt) * 2006-11-09 2017-06-06 Ardea Biosciences Inc compostos heterocíclicos bicíclicos substituidos por 4-cianofenilamino como inibidores de hiv
NZ577197A (en) 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
DK2091918T3 (en) * 2006-12-08 2014-12-01 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US7981903B2 (en) * 2007-08-08 2011-07-19 Glaxosmithkline Llc 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer
ES2659980T3 (es) 2007-08-29 2018-03-20 Senju Pharmaceutical Co., Ltd. Agente para promover la adherencia de células endoteliales de la córnea
AU2008305294B2 (en) * 2007-09-21 2012-11-29 Array Biopharma Inc. Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
MX2010003346A (es) 2007-10-19 2010-04-09 Boehringer Ingelheim Int Piperazino-dihidrotienopirimidinas sustituidas en heterociclo.
EA019480B1 (ru) 2007-10-19 2014-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные пиперидинодигидротиенопиримидины в качестве ингибиторов pde4
CA2702518A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh New piperazino-dihydrothienopyrimidine derivatives
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
EP2265270A1 (de) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridin-kinase-inhibitoren
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
DK2421957T3 (da) * 2009-04-22 2021-01-25 Viacyte Inc Cellesammensætninger afledt af dedifferentierede omprogrammerede celler
CA2929545C (en) * 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
US8415155B2 (en) 2009-10-19 2013-04-09 Cellular Dynamics International, Inc. Cardiomyocyte production
CN102574843B (zh) 2009-10-22 2015-06-17 法博太科制药有限公司 抗纤维化剂的稠环类似物
WO2011079230A2 (en) * 2009-12-23 2011-06-30 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
EP2528606B1 (de) 2010-01-28 2014-09-24 Alexander Levitzki Auf chinazolin basierende t-zell-proliferationshemmer
JP5984217B2 (ja) 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
CN103442568A (zh) * 2010-10-08 2013-12-11 Abbvie公司 呋喃并[3,2-d]嘧啶化合物
WO2012065067A2 (en) 2010-11-12 2012-05-18 Georgetown University Immortalization of epithelial cells and methods of use
AU2011329486A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
KR102482184B1 (ko) 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US9006241B2 (en) 2011-03-24 2015-04-14 Noviga Research Ab Pyrimidine derivatives
EP2502924A1 (de) 2011-03-24 2012-09-26 Chemilia AB Neue Pyrimidinderivate
CA2831609C (en) 2011-03-30 2019-06-11 Cellular Dynamics International, Inc. Priming of pluripotent stem cells for neural differentiation
JP6121658B2 (ja) * 2011-06-29 2017-04-26 大塚製薬株式会社 治療用化合物、及び関連する使用の方法
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
EP3517604A1 (de) 2011-12-06 2019-07-31 Astellas Institute for Regenerative Medicine Verfahren für eine gezielte differenzierung zur produktion von hornhautendothelzellen
EP3553169B1 (de) 2011-12-28 2021-11-03 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
WO2013137491A1 (ja) 2012-03-15 2013-09-19 国立大学法人京都大学 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
EP2837681B1 (de) 2012-04-06 2018-02-21 Kyoto University Verfahren zur induzierung erythropoietinproduzierender zellen
EP2711365A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
EP2711364A1 (de) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl oder benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidine verwendbar für die Behandlung von Krebs
WO2014105958A2 (en) 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US9415043B2 (en) 2013-03-15 2016-08-16 Aerie Pharmaceuticals, Inc. Combination therapy
EP2981605B1 (de) 2013-04-03 2019-06-19 FUJIFILM Cellular Dynamics, Inc. Verfahren und zusammensetzungen zur kultivierung von endoderm-vorläuferzellen in einer suspension
US10961508B2 (en) 2013-04-12 2021-03-30 Kyoto University Method for inducing alveolar epithelial progenitor cells
BR112015030918A2 (pt) 2013-06-11 2017-12-05 Astellas Pharma Inc método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
JP6548576B2 (ja) 2013-07-30 2019-07-24 京都府公立大学法人 角膜内皮細胞マーカー
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
US11473058B2 (en) 2013-09-05 2022-10-18 Kyoto University Method for inducing dopaminergic neuron progenitor cells
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
PL3064222T3 (pl) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Lek terapeutyczny zawierający inhibitor sygnału tgf-beta w chorobach związanych z retikulum endoplazmatycznym i śmiercią komórki w śródbłonku rogówki
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
RU2704984C1 (ru) 2013-11-27 2019-11-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Применение ламинина в культуре клеток эндотелия роговицы
EP2905024A1 (de) 2014-02-07 2015-08-12 Institut Quimic De Sarriá Cets, Fundació Privada Pyrido[2,3-d]pyrimidin-7(8H)-on-Derivate zur Behandlung von Flaviviridae Infectionen
KR102340553B1 (ko) 2014-03-04 2021-12-21 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
US9694036B2 (en) 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
EP3147353B1 (de) 2014-05-21 2022-03-30 Kyoto University Verfahren zur herstellung von pankreasblasten und pankreaskrankheitsbehandlungsmittel mit pankreasblasten
MX2017000181A (es) 2014-06-27 2017-05-01 Univ California Celulas madre limbales de mamifero cultivadas, metodos para generarlas y sus usos.
JP7253692B2 (ja) 2014-12-26 2023-04-07 国立大学法人京都大学 肝細胞誘導方法
CN104530078B (zh) * 2015-01-27 2017-03-22 山东大学 一种噻吩并[3,2‑d]嘧啶衍生物及其制备方法与应用
EP3822339A1 (de) 2015-04-03 2021-05-19 Propagenix Inc. Ex-vivo-proliferation von epithelzellen
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
US10273248B2 (en) 2015-06-26 2019-04-30 Kadmon Corportion, LLC Glucose uptake inhibitors
WO2016210331A1 (en) * 2015-06-26 2016-12-29 Kadmon Corporation, Llc Treatment of infectious diseases with glucose uptake inhibitors
JP2018522867A (ja) * 2015-06-26 2018-08-16 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 縮合二環式ピリミジン誘導体およびこれらの使用
EP3892718A1 (de) 2015-09-11 2021-10-13 Propagenix Inc. Ex-vivo-proliferation von epithelzellen
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
KR20180092951A (ko) 2015-10-30 2018-08-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2017096100A1 (en) * 2015-12-03 2017-06-08 Shanghai Aeon Biotech Co., Ltd. Heterocycle compounds and uses thereof
US10829495B2 (en) 2015-12-03 2020-11-10 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
EP3394056B1 (de) 2015-12-22 2021-04-14 Shy Therapeutics LLC Verbindungen zur behandlung von krebs und entzündungskrankheiten
EP4218773A1 (de) 2016-02-15 2023-08-02 Kyoto Prefectural Public University Corporation Menschliche funktionelle hornhautendothelzelle und anwendung davon
KR102312123B1 (ko) 2016-04-22 2021-10-13 고쿠리츠 다이가쿠 호진 교토 다이가쿠 도파민 생산 신경전구세포의 제조방법
CN107652273B (zh) * 2016-07-26 2020-05-01 沈阳药科大学 嘧啶类衍生物及其制备方法和应用
JP7120993B2 (ja) 2016-08-16 2022-08-17 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性細胞を分化させるための方法
AU2017319520A1 (en) 2016-08-31 2019-03-07 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
KR20190115451A (ko) 2017-02-03 2019-10-11 세르타 테라퓨틱스 피티와이 엘티디. 항-섬유성 화합물
AU2018243687C1 (en) 2017-03-31 2020-12-24 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN110662832B (zh) 2017-05-25 2024-01-05 国立大学法人京都大学 由间介中胚层细胞分化诱导肾祖细胞的方法和由多能干细胞分化诱导肾祖细胞的方法
JP2020524703A (ja) 2017-06-21 2020-08-20 シャイ・セラピューティクス・エルエルシーＳｈｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
US10323023B2 (en) 2017-06-30 2019-06-18 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN110573501B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US11613531B2 (en) 2017-09-01 2023-03-28 Kadmon Corporation, Llc Inhibitors of RHO associated coiled-coil containing protein kinase
WO2019092939A1 (ja) 2017-11-10 2019-05-16 株式会社リジェネシスサイエンス 培養細胞の製造方法，脊髄損傷疾患の治療剤の製造方法
CN111788300A (zh) 2017-12-28 2020-10-16 株式会社钟化 细胞聚集抑制剂
US20220267736A1 (en) 2017-12-28 2022-08-25 Kaneka Corporation Pluripotent stem cell aggregation suppressor
WO2019131942A1 (ja) 2017-12-28 2019-07-04 株式会社カネカ 細胞凝集促進剤
WO2019160148A1 (ja) 2018-02-19 2019-08-22 大日本住友製薬株式会社 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
WO2020022261A1 (ja) 2018-07-23 2020-01-30 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP3841195A1 (de) 2018-08-20 2021-06-30 Propagenix Inc. Epithelzellsphäroide
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
WO2020045642A1 (ja) 2018-08-31 2020-03-05 学校法人同志社 眼細胞を保存または培養するための組成物および方法
AU2019337703B2 (en) 2018-09-14 2023-02-02 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP3862424A4 (de) 2018-10-02 2022-06-29 The Doshisha Verfahren und gefäss zur konservierung von hornhautzellen
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
SG11202105214VA (en) * 2018-11-30 2021-06-29 Celularity Inc Aromatic compounds for use in activating hematopoietic stem and progenitor cells
US20220056413A1 (en) 2018-12-21 2022-02-24 Kyoto University Lubricin-localized cartilage-like tissue, method for producing same and composition comprising same for treating articular cartilage damage
WO2020193802A1 (en) 2019-03-28 2020-10-01 Fundación De La Comunidad Valenciana Centro De Investigación Príncipe Felipe Polymeric conjugates and uses thereof
EP3950933A4 (de) 2019-03-29 2023-01-11 Kaneka Corporation Zellpopulation mit pluripotenten stammzellen und verfahren zu ihrer herstellung
WO2020230832A1 (ja) 2019-05-15 2020-11-19 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
WO2021172554A1 (ja) 2020-02-27 2021-09-02 京都府公立大学法人 ヒト機能性角膜内皮細胞およびその応用
EP4142879A1 (de) 2020-04-27 2023-03-08 Novartis AG Verfahren und zusammensetzungen zur augenzelltherapie
CN116802276A (zh) 2021-01-08 2023-09-22 国立大学法人京都大学 用于扩增培养肾元祖细胞的培养基、扩增培养肾元祖细胞的方法以及肾脏类器官的制造方法
JP2024513912A (ja) 2021-04-07 2024-03-27 フジフィルム セルラー ダイナミクス，インコーポレイテッド ドーパミン作動性前駆細胞（ｐｒｅｃｕｒｓｏｒ ｃｅｌｌ）及び使用方法
KR20240005837A (ko) 2021-05-03 2024-01-12 아스텔라스 인스티튜트 포 리제너러티브 메디슨 성숙한 각막 내피 세포의 생성 방법
WO2022259721A1 (ja) 2021-06-10 2022-12-15 味の素株式会社 間葉系幹細胞の製造方法
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
CA3231501A1 (en) 2021-09-13 2023-03-16 Steven Kattman Methods for the production of committed cardiac progenitor cells
WO2023069949A1 (en) 2021-10-18 2023-04-27 Evia Life Sciences Inc. Compositions and methods of use thereof for treating liver fibrosis
WO2023067394A2 (en) 2021-10-22 2023-04-27 Evia Life Sciences Inc. Methods for making extracellular vesicles, and compositions and methods of use thereof
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642347A (en) * 1985-05-21 1987-02-10 American Home Products Corporation 3(2-quinolinylalkoxy)phenols
US5245038A (en) * 1987-11-06 1993-09-14 Baxter Diagnostics Inc. Fluorescent poly(arylpyridine) rare earth chelates
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
MX9200299A (es) * 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
US6004979A (en) * 1991-02-07 1999-12-21 Hoechst Marion Roussel Nitrogenous bicycles
DK0498722T3 (da) * 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
US5245036A (en) * 1992-05-07 1993-09-14 Dowelanco Process for the preparation of 4-phenoxyquinoline compounds
US5972598A (en) * 1992-09-17 1999-10-26 Board Of Trustess Of The University Of Illinois Methods for preventing multidrug resistance in cancer cells
EP1195372A1 (de) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-Heterozyklisch substitutierte Benzamid Deriviate mit antihypertensiver Wirkung
US5840695A (en) * 1994-10-07 1998-11-24 Heska Corporation Ectoparasite saliva proteins and apparatus to collect such proteins
JP3290666B2 (ja) * 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
KR100576148B1 (ko) * 1996-08-12 2006-05-03 미쯔비시 웰 파마 가부시키가이샤 Ｒｈｏ 키나아제 억제제를 함유하는　약제
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5885803A (en) * 1997-06-19 1999-03-23 Incyte Pharmaceuticals, Inc. Disease associated protein kinases
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
CA2214841A1 (en) 1997-10-31 1999-04-30 Lisa Mckerracher Rho antagonists and their use to block inhibition of neurite outgrowth
EP1028964A1 (de) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidin- und thienopyridin-derivate als antikrebsmittel
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
ID26698A (id) * 1998-06-19 2001-02-01 Pfizer Prod Inc SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
EP1459743B9 (de) 1998-08-17 2012-08-01 Senju Pharmaceutical Co., Ltd. Verbindung zur Vorbeugung und Behandlung von Glaukoma
HUP0103386A3 (en) * 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
SE515247C2 (sv) 1998-09-04 2001-07-02 Alfa Laval Agri Ab Djurbås med fösningsorgan
EP1141081B1 (de) * 1998-12-23 2006-05-24 Bayer MaterialScience AG Polycarbonate mit niedrigem yellowness-index
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911510A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
KR100704704B1 (ko) 1999-03-25 2007-04-09 미쯔비시 웰 파마 가부시키가이샤 간질성 폐렴·폐섬유증의 예방·치료약
AU3328600A (en) 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
EP1174150A4 (de) 1999-04-22 2004-06-16 Mitsubishi Pharma Corp Präventiv-/heilmittel für angiostenose
AU4144400A (en) 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
AU1212501A (en) 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
AU2001293817A1 (en) 2000-09-20 2002-04-02 Merck Patent Gmbh 4-amino-quinazolines
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2002053143A2 (en) 2001-01-05 2002-07-11 The Medical College Of Georgia Research Institute, Inc. Treatment of erectile dysfunction with rho-kinase inhibitors
MXPA03008658A (es) * 2001-03-23 2005-04-11 Bayer Ag Inhibidores de rho-cinasa.
EP1470122B1 (de) * 2002-01-23 2007-12-19 Bayer Pharmaceuticals Corporation Rho-kinase inhibitoren

Also Published As

Publication number Publication date
AU2003202263A1 (en) 2003-07-30
JP4505228B2 (ja) 2010-07-21
US20100216789A1 (en) 2010-08-26
ES2305435T3 (es) 2008-11-01
WO2003059913A1 (en) 2003-07-24
US20070238741A1 (en) 2007-10-11
EP1465900A1 (de) 2004-10-13
JP2005523251A (ja) 2005-08-04
EP1465900B1 (de) 2008-05-14
CA2472619A1 (en) 2003-07-24
US7648986B2 (en) 2010-01-19
US20040014755A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
DE60320933D1 (de) Rho-kinase inhibitoren
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DE602004018837D1 (de) Ptidase-iv-inhibitoren
DE60234125D1 (de) E inhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
DK1505963T3 (da) Hepatitis C-inhibitorer
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
NO20054852D0 (no) GFAT inhibitorer
IS7599A (is) Heterósýklískir kínasatálmar
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
ATE333454T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
DK1569712T3 (da) Forbindelsesindretning
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
ATE286049T1 (de) Pyridazinonaldose reductase inhibitoren
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
EE200300450A (et) Metalloproteinaasi inhibiitorid
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DK1501804T3 (da) Isoquinolinderivat MAO-B-inhibitorer
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
NO20034109L (no) Parafininhibitor-komposisjon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE